Amisulpride
Brand names: Barhemsys · Active ingredient: Amisulpride
In short: BARHEMSYS® is indicated in adults for: prevention of postoperative nausea and vomiting (PONV), either alone or in combination with an antiemetic of a different class. treatment of PONV in patients who have received antiemetic prophylaxis with an agent of a different class or have not received prophy
What is Amisulpride used for?
BARHEMSYS® is indicated in adults for:
prevention of postoperative nausea and vomiting (PONV), either alone or in combination with an antiemetic of a different class.
treatment of PONV in patients who have received antiemetic prophylaxis with an agent of a different class or have not received prophylaxis.
Amisulpride dosage
The recommended adult dosage of BARHEMSYS and infusion rate by indication is shown in the table below:
Indication | Adult Dosage Regimen
Prevention of PONV | 5 mg as a single intravenous injection infused over 1 to 2 minutes at the time of induction of anesthesia .
Treatment of PONV | 10 mg as a single intravenous injection infused over 1 to 2 minutes in the event of nausea and/or vomiting after a surgical procedure .
Dilution of BARHEMSYS is not required before administration. BARHEMSYS is chemically and physically compatible with Water for Injection, 5% Dextrose Injection, 0.9% Sodium Chloride Injection, and Lactated Ringer's Solution (also known as Ringer's Lactate Solution, Compound Sodium Lactate Solution, and Hartmann's Solution), any of which may be used to flush an intravenous line before or after administration of BARHEMSYS.
Protect from light. BARHEMSYS is subject to photodegradation. Administer BARHEMSYS within 12 hours of removal of the vial from the protective carton.
Prior to administration, inspect the BARHEMSYS solution visually for particulate matter and discoloration. Discard if particulate matter or discoloration is observed.
How to take Amisulpride — instructions & advice from the label
QT Prolongation
Instruct patients to contact their healthcare provider immediately if they perceive a change in their heart rate, if they feel lightheaded, or if they have a syncopal episode .
Drug Interactions
Advise patients to report to their healthcare provider if they are taking drugs which prolong the QT interval .
Lactation
Women may consider reducing infant exposure through pumping and discarding breastmilk for 48 hours after BARHEMSYS administration .
Warnings & precautions
Do not take this medicine if: BARHEMSYS is contraindicated in patients with known hypersensitivity to amisulpride .
BARHEMSYS causes dose- and concentration-dependent prolongation of the QT interval . The recommended dosage is 5 or 10 mg as a single intravenous dose infused over 1 to 2 minutes .
Avoid use in patients with congenital long QT syndrome and in patients taking droperidol.
Electrocardiogram (ECG) monitoring is recommended in patients with pre-existing arrhythmias/cardiac conduction disorders; electrolyte abnormalities (e.g., hypokalemia or hypomagnesemia); congestive heart failure; and in patients taking other medicinal products (e.g., ondansetron) or with other medical conditions known to prolong the QT interval .
Amisulpride side effects
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The data described below reflect exposure to BARHEMSYS in 1,166 patients treated in placebo-controlled trials. 748 of these patients received a dose of 5 mg for prevention of PONV (of whom 572 received another antiemetic concomitantly) and 418 patients received 10 mg for treatment of PONV . The mean age of the population was 49 years (range 18 to 91 years), 87% female, 80% White/Caucasian, 9% Black, and 1% Asian.
Prevention of PONV
Common adverse reactions reported in at least 2% of adult patients who received BARHEMSYS 5 mg and at a higher rate than placebo in Studies 1 and 2 for the prevention of PONV are shown in Table 1.
BARHEMSYS 5 mg | Placebo
N=748 | N=741
Chills | 4% | 3%
Hypokalemia | 4% | 2%
Procedural hypotension | 3% | 2%
Abdominal distension | 2% | 1%
Serum prolactin concentrations were measured in Study 1 where 5% (9/176) of BARHEMSYS-treated patients vs 1% (1/166) of placebo-treated patients had increased blood prolactin reported as an adverse reaction. Serum prolactin concentrations increased from a mean of 10 ng/mL at baseline to 32 ng/mL after BARHEMSYS treatment in 112 females (upper limit of normal 29 ng/mL) and from 10 ng/mL to 19 ng/mL in 61 males (upper limit of normal 18 ng/mL). …
Drug interactions
Reciprocal antagonism of effects occurs between dopamine agonists (e.g., levodopa) and BARHEMSYS. Avoid using levodopa with BARHEMSYS.
BARHEMSYS causes dose- and concentration-dependent QT prolongation . To avoid potential additive effects, avoid use of BARHEMSYS in patients taking droperidol. ECG monitoring is recommended in patients taking other drugs known to prolong the QT interval (e.g., ondansetron) .
About this medicine
The active ingredient of BARHEMSYS is amisulpride, a dopamine-2 (D2) receptor antagonist. Its chemical name is 4-Amino-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-(ethylsulfonyl)-o-anisamide. It has the following chemical structure:
(racemic)
The empirical formula is C17H27N3O4S representing a molecular weight of 369.48.
Amisulpride is a white or almost white crystalline powder. It is practically insoluble in water, sparingly soluble in ethanol and freely soluble in methylene chloride, and has a melting point of around 126°C. The compound is racemic and shows no optical rotation and is not hygroscopic. No other polymorphs of amisulpride have been reported.
BARHEMSYS (amisulpride) injection is a clear, colorless, nonpyrogenic, sterile solution formulation of amisulpride 5 mg/2 mL (2.5 mg/mL) or 10 mg/4 mL (2.5 mg/mL) for intravenous infusion presented in a single-dose vial. It has a pH of approximately 5.0 and the osmolality of the product is between 250 and 330 mOsmol/kg. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID ab23bc6e-b6a8-165f-e053-2a95a90ab144. Read the full official label on DailyMed.
Related medicines
Omeprazole Pantoprazole Fluoxetine Amoxicillin Famotidine Ondansetron Esomeprazole Docusate